Similarly, preclinical studies in Brca1/2-deficient breast cancer mouse models showed that olaparib, a selective PARP inhibitor, enhanced the anti-tumor efficacy of platinum-based therapies, leading to profound tumor growth suppression [401,402]. This evidence concerns the gene BRCA1 and neoplasm.